<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20251202068188N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-04-22</date_registration>
      <primary_sponsor>Bagheiat-allah University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of a person-centered self-care educational intervention on quality of life and fatigue in women with breast cancer</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of a person-centered self-care educational intervention delivered through telenursing on quality of life and fatigue in women with breast cancer</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>76</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/88038</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: The sampling method was purposive, and participants were selected from among patients referring to Imam Reza Hospital according to the inclusion criteria. Subsequently, in order to randomly allocate participants into two groups (intervention and control), block randomization with a block size of four was used.
Accordingly, the letter A was assigned to the intervention group and the letter B to the control group. Then, six possible arrangements (AABB, BBAA, ABBA, BAAB, ABAB, BABA) were written on separate sheets of paper and placed into a container. One sheet was randomly selected, and the sequence written on it was recorded and then returned to the container. This procedure was repeated 19 times, and each time the selected sequence was recorded consecutively until the total sample size of 76 was achieved.
Numbers from 1 to 76 were assigned to each letter. Each letter was placed in a separate envelope, and the envelopes were labeled with numbers from 1 to 76. Each time a participant was enrolled, the envelopes were opened sequentially, and in this manner it was determined whether the participant was allocated to the intervention or the control group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Breast cancer.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Five weekly sessions of a personalized self-care educational intervention delivered through telenursing. Educational content includes voice-over slides covering self-care strategies tailored to each participant’s needs. Each participant receives a 15–30 minute telephone consultation every two weeks, providing individualized guidance and answers to questions. Total duration of the intervention: 10 weeks (including weekly educational materials and biweekly calls). Intervention 2: Control group: Participants receive standard care provided by the medical center, without additional personalized self-care educational intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All above-mentioned data and documents will be available after study completion in de-identified form. They can be accessed upon written request to the research team, and eligible researchers may use them for scientific research purposes only.

When:
Access will begin six months after publication of study results and continue for five years thereafter.

To whom:
Researchers affiliated with academic and research institutions with approved scientific objectives.

Conditions:
Data may only be used for scientific research purposes and statistical analyses. Commercial use or publication of data without explicit permission from the research team is not allowed.

Where to obtain:
Applicants should send a written request to the research team via email at: info@baghiatallah.ac.ir

How to obtain:
1. Submit a written request to the research team via email  
2. Review and approval of the request by the research team  
3. Signing a data use agreement by the applicant  
4. Provision of de-identified data and documents to the applicant  
5. Use of data exclusively for scientific research purposes

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Foroozan Faghihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 12, Unit 7, Sadati Alley, East Mahboob Majaz, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1333638658</zip>
        <telephone>+98 31 5328 8305</telephone>
        <email>foroozan.fgh@gmail.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Foroozan Faghihi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 12, Unit 7, Sadati Alley, East Mahboob Majaz, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1333638658</zip>
        <telephone>+98 31 5328 8305</telephone>
        <email>foroozan.fgh@gmail.com</email>
        <affiliation>Bagheiat-allah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with breast cancer referred to the selected medical center of the armed forces (Emam Reza Hospital) in Tehran in 1404
Ability to work with software applications and mobile devices
Patients undergoing chemotherapy, chemotherapy following radiation therapy, or chemotherapy following surgery</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness to receive the educational program
Rapid disease progression or widespread metastasis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>C50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasm of breast</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Five weekly sessions of a personalized self-care educational intervention delivered through telenursing. Educational content includes voice-over slides covering self-care strategies tailored to each participant’s needs. Each participant receives a 15–30 minute telephone consultation every two weeks, providing individualized guidance and answers to questions. Total duration of the intervention: 10 weeks (including weekly educational materials and biweekly calls)</i_keyword>
      <i_keyword>Control group: Participants receive standard care provided by the medical center, without additional personalized self-care educational intervention</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Quality of life score of women with breast cancer based on the breast cancer–specific quality of life questionnaire. Timepoint: Measurement of quality of life at baseline (before the intervention) and at the end of the personalized self-care educational intervention delivered through tele-nursing. Method of measurement: Thirty-item breast cancer quality of life questionnaire assessing functional domains, symptom subscales, and global quality of life.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fatigue score of women with breast cancer in physical, cognitive, and emotional dimensions. Timepoint: Measurement of fatigue at baseline (before the intervention) and at the end of the personalized self-care educational intervention delivered through telenursing. Method of measurement: A fifteen-item cancer-related fatigue questionnaire assessing fatigue in the physical, cognitive, and emotional dimensions.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Bagheiat-allah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-11-26</approval_date>
        <contact_name>Ethics Committee of Baqiyatallah University of Medical Sciences</contact_name>
        <contact_address>13th Floor, Block A, Central Headquarters of the Ministry of Health, Treatment and Medical Education, Simaye Iran Street, between Flamk Jonoubi and Zarfshan, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
